General Information of Drug Transporter (DT)
DT ID	DTD0030 Transporter Info
Gene Name	SLCO1B3
Protein Name	Organic anion transporting polypeptide 1B3
Gene ID	28234
UniProt ID	Q9NPD5
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs11045585
Site of GPD	chr12:20892760 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.1552/777 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           5 Drugs in Total
Docetaxel	Drug Info	Neoplasm	Correlated with the increased leukopenia risk in patients (compare with Allele A)		[ 1]
Docetaxel	N.A.	Parasitemia	Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.		[ 2]
Docetaxel	N.A.	Leukopenia	Allele G is associated with increased risk of Leukopenia when treated with docetaxel as compared to allele A.		[ 1]
Docetaxel	N.A.	Neoplasms	Allele G is associated with increased risk of Leukopenia when treated with docetaxel as compared to allele A.		[ 1]
Docetaxel	N.A.	Neoplasms	Allele G is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.		[ 2]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Docetaxel	N.A.	Neutropenia	Genotype AA is not associated with Neutropenia when treated with docetaxel in people with Neoplasms as compared to genotypes AG + GG.		[ 3]
Docetaxel	N.A.	Leukopenia	Genotype AA is not associated with clearance of docetaxel as compared to genotypes AG + GG.		[ 3]
Docetaxel	N.A.	Neoplasms	Patients with the AA genotype and Neoplasms who are treated with docetaxel may have 1) a decreased, but not absent, risk of leukopenia, 2) an increased clearance of docetaxel as compared to patients with the AG or GG genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Docetaxel	N.A.	Neoplasms	Patients with the AG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Docetaxel	N.A.	Neoplasms	Patients with the GG genotype and Neoplasms who are treated with docetaxel may have 1) an increased risk of leukopenia, 2) a decreased clearance of docetaxel as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's response to docetaxel.		[ 1]
Genetic Polymorphism	rs4149117
Site of GPD	chr12:20858546 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>C / T>G
Minor Allele Frequency	T=0.2975/1490 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the decreased dose-normalized Cmax and dose-normalized AUC0to12 h in patients (compare with Allele T); Correlated with the increased adverse drug reactions risk in patients (compare with Allele T); Irrelevant to the drug clearance in patients (compare with Allele T)		[ 4], [ 5]
Methotrexate	N.A.	Parasitemia	Allele G is not associated with transport of methotrexate in HEK293 cells as compared to allele T.		[ 6]
Mycophenolate Mofetil	N.A.	Parasitemia	Allele G is associated with decreased dose-normalized Cmax and dose-normalized AUC0to12 h when treated with mycophenolate mofetil in people with kidney transplants as compared to allele T.		[ 5]
Mycophenolate Mofetil	N.A.	Drug Toxicity	Allele G is associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.		[ 4]
Tacrolimus	N.A.	Peripheral Nervous System Diseases	Allele G is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele T.		[ 7]
Bosentan	N.A.	Drug-induced Liver Injury	Allele G is not associated with increased risk of drug-induced liver injury when treated with bosentan in people with Hypertension, Pulmonary as compared to allele T.		[ 8]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Allele G is not associated with clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.		[ 5]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Allele G is associated with increased risk of adverse drug reactions when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele T.		[ 4]
Allele T	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Irrelevant to the increased leukopenia risk in patients (compare with allele G)		[ 9]
Azathioprine	N.A.	Overall Survival	Allele T is not associated with likelihood of overall survival when treated with azathioprine in people with lung transplantation as compared to allele G.		[ 10]
Azathioprine	N.A.	Transplant Rejection	Allele T is not associated with risk of transplant rejection when treated with azathioprine in people with lung transplantation as compared to allele G.		[ 10]
Azathioprine	N.A.	Chronic Lung Allograft Dysfunction	Allele T is not associated with risk of chronic lung allograft dysfunction when treated with azathioprine in people with lung transplantation as compared to allele G.		[ 10]
Imatinib	N.A.	Leukopenia	Allele T is not associated with dose of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 11]
Imatinib	N.A.	Drug Toxicity	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 11]
Imatinib	N.A.	Discontinuation	Allele T is not associated with risk of Drug Toxicity and Discontinuation of imatinib in people with Gastrointestinal Stromal Tumors as compared to allele G.		[ 11]
Mycophenolate Mofetil	N.A.	Leukopenia	Allele T is not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 9]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Allele T is not associated with increased risk of Leukopenia when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 9]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:         20 Drugs in Total
Sunitinib	Drug Info	Gastrointestinal Stromal Tumors	Correlated with the decreased overall survival in patients (compare with Genotypes GT + TT)		[ 12]
Paclitaxel	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased anemia risk in patients (compare with Genotypes GT + TT)		[ 13]
Carboplatin	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased anemia risk in patients (compare with Genotypes GT + TT)		[ 13]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the increased dose-adjusted area under the curve of mycophenolic acid in patients (AUC6-12) (compare with Genotype TT)		[ 14]
Mycophenolate Mofetil	N.A.	Neutropenia	Genotype GG is associated with increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.		[ 14]
Imatinib	N.A.	Drug Toxicity	Genotype GG is associated with increased dose-adjusted trough concentrations of imatinib in people with Gastrointestinal Stromal Tumors as compared to genotypes GT + TT.		[ 15]
Carboplatin	N.A.	Anemia	Genotype GG is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 13]
Paclitaxel	N.A.	Anemia	Genotype GG is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 13]
Mycophenolate Mofetil	N.A.	Gastrointestinal Toxicity	Genotype GG is associated with increased likelihood of gastrointestinal toxicity when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.		[ 16]
Warfarin	N.A.	Gastrointestinal Toxicity	Genotype GG is associated with decreased dose of warfarin as compared to genotypes GT + TT.		[ 17]
Sunitinib	N.A.	Overall Survival	Genotype GG is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to genotypes GT + TT.		[ 12]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Genotype GG is associated with increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype TT.		[ 14]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the GG genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.		[ 9]
Carboplatin	N.A.	Lung Neoplasms	Genotype GG is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 13]
Paclitaxel	N.A.	Lung Neoplasms	Genotype GG is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes GT + TT.		[ 13]
Sunitinib	N.A.	Gastrointestinal Stromal Tumors	Genotype GG is associated with decreased overall survival when treated with sunitinib in people with Gastrointestinal Stromal Tumors as compared to genotypes GT + TT.		[ 12]
Mycophenolic Acid	N.A.	Lung Transplantation	Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Overall Survival	Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Chronic Lung Allograft Dysfunction	Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Transplant Rejection	Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the GT or TT genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the increased diarrhea risk in patients (compare with genotype GG); Correlated with the increased diarrhea risk in patients (compare with genotype Gt)		[ 9]
Paclitaxel	N.A.	Peripheral Nervous System Diseases	Genotype TT is associated with increased severity of Peripheral Nervous System Diseases when treated with paclitaxel in women with Breast Neoplasms as compared to genotypes GG + GT.		[ 19]
Mycophenolate Mofetil	N.A.	Diarrhea	Genotype TT is associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.		[ 9]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Genotype TT is associated with increased risk of Diarrhea when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.		[ 9]
Carboplatin	N.A.	Lung Neoplasms	Patients with the TT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.		[ 13]
Paclitaxel	N.A.	Lung Neoplasms	Patients with the TT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.		[ 13]
Sunitinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the TT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.		[ 12]
Mycophenolic Acid	N.A.	Lung Transplantation	Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Overall Survival	Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Chronic Lung Allograft Dysfunction	Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Transplant Rejection	Patients with the TT genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Genotypes GT + TT	Click to Show/Hide the Full List of Affected Drugs:         11 Drugs in Total
Paclitaxel	Drug Info	Lung Neoplasm; Malignant Tumor Of Peritoneum; Ovarian Neoplasm; Uterine Neoplasm	Correlated with the decreased likelihood of thrombocytopenia in patients (compare with genotype GG)		[ 19]
Carboplatin	Drug Info	Lung Neoplasm; Malignant Tumor Of Peritoneum; Ovarian Neoplasm; Uterine Neoplasm	Correlated with the decreased likelihood of thrombocytopenia in patients (compare with genotype GG)		[ 19]
Mycophenolic Acid	N.A.	Chronic Lung Allograft Dysfunction	Genotypes GT + TT are associated with increased risk of chronic lung allograft dysfunction when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.		[ 10]
Mycophenolic Acid	N.A.	Transplant Rejection	Genotypes GT + TT are associated with increased risk of transplant rejection when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.		[ 10]
Mycophenolic Acid	N.A.	Overall Survival	Genotypes GT + TT are associated with decreased likelihood of overall survival when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.		[ 10]
Voriconazole	N.A.	Leukopenia	Genotypes GT + TT is associated with decreased trough concentration of voriconazole in children as compared to genotype GG.		[ 21]
Carboplatin	N.A.	Thrombocytopenia	Genotypes GT + TT is associated with decreased likelihood of Thrombocytopenia when treated with carboplatin and paclitaxel in people with Lung Neoplasms, Malignant tumor of peritoneum, Neoplasms, Ovarian Neoplasms or Uterine Neoplasms as compared to genotype GG.		[ 19]
Paclitaxel	N.A.	Thrombocytopenia	Genotypes GT + TT is associated with decreased likelihood of Thrombocytopenia when treated with carboplatin and paclitaxel in people with Lung Neoplasms, Malignant tumor of peritoneum, Neoplasms, Ovarian Neoplasms or Uterine Neoplasms as compared to genotype GG.		[ 19]
Carboplatin	N.A.	Lung Neoplasms	Genotypes GT + TT is associated with decreased likelihood of Thrombocytopenia when treated with carboplatin and paclitaxel in people with Lung Neoplasms, Malignant tumor of peritoneum, Neoplasms, Ovarian Neoplasms or Uterine Neoplasms as compared to genotype GG.		[ 19]
Paclitaxel	N.A.	Lung Neoplasms	Genotypes GT + TT is associated with decreased likelihood of Thrombocytopenia when treated with carboplatin and paclitaxel in people with Lung Neoplasms, Malignant tumor of peritoneum, Neoplasms, Ovarian Neoplasms or Uterine Neoplasms as compared to genotype GG.		[ 19]
Mycophenolic Acid	N.A.	Lung Transplantation	Genotypes GT + TT are associated with decreased likelihood of overall survival when treated with mycophenolic acid in people with lung transplantation as compared to genotype GG.		[ 10]
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Neutropenia	Genotypes GG + GT is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype TT.		[ 21]
Tacrolimus	N.A.	Drug Toxicity	Genotypes GG + GT is associated with increased dose-adjusted trough concentrations of tacrolimus in people with lung transplantation as compared to genotype TT.		[ 22]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the GT genotype who are renal transplant recipients and are treated with mycophenolate mofetil: 1) may have an increased risk of adverse drug reactions 2) may have decreased exposure to active mycophenolic acid as compared to patients with the TT genotype, or 1) may have a decreased risk of adverse drug reactions 2) may have increased exposure to active mycophenolic acid as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for drug-induced toxicity and exposure to mycophenolic acid.		[ 9]
Carboplatin	N.A.	Lung Neoplasms	Patients with the GT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.		[ 13]
Paclitaxel	N.A.	Lung Neoplasms	Patients with the GT genotype and Lung Neoplasms who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia and thrombocytopenia as compared to patients with the GG genotype. Other genetic and clinical factors may also influence a patient's risk for anemia and thrombocytopenia.		[ 13]
Sunitinib	N.A.	Gastrointestinal Stromal Tumors	Patients with the GT genotype and gastrointestinal stromal tumors (GIST) may have longer overall survival times when treated with sunitinib as compared to patients with the GG genotype. Other genetic and clinical factors may also influence overall survival time.		[ 12]
Mycophenolic Acid	N.A.	Lung Transplantation	Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Overall Survival	Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Chronic Lung Allograft Dysfunction	Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Transplant Rejection	Patients with the GT genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the GG genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Genetic Polymorphism	rs7311358
Site of GPD	chr12:20862826 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.2975/1490 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:         12 Drugs in Total
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the decreased drug clearance in patients (compare with allele G); Irrelevant to the drug clearance in patients (compare with allele G)		[ 5]
Paclitaxel	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the decreased transport of drug (compare with allele G)		[ 13]
Methotrexate	N.A.	Parasitemia	Allele A is not associated with transport of methotrexate in HEK293 cells as compared to allele G.		[ 6]
Docetaxel	N.A.	Parasitemia	Allele A is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.		[ 2]
Methotrexate	N.A.	Drug Toxicity	Allele A is not associated with increased likelihood of Drug Toxicity when treated with methotrexate in children with Acute lymphoblastic leukemia as compared to allele G.		[ 27]
Paclitaxel	N.A.	Drug Toxicity	Allele A is associated with decreased transport of paclitaxel in oocytes as compared to allele G.		[ 13]
Mycophenolate Mofetil	N.A.	Drug Toxicity	Allele A is not associated with clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 5]
Tenofovir	N.A.	Drug Toxicity	Allele A is not associated with clearance of tenofovir in people with HIV Infections as compared to allele G.		[ 28]
Tacrolimus	N.A.	Peripheral Nervous System Diseases	Allele A is not associated with trough concentration of tacrolimus in people with Kidney Transplantation and Transplantation as compared to allele G.		[ 7]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Allele A is associated with decreased clearance of mycophenolate mofetil in people with Kidney Transplantation as compared to allele G.		[ 5]
Carboplatin	N.A.	Non-small Cell Lung Carcinoma	Allele A is associated with decreased transport of paclitaxel in oocytes as compared to allele G.		[ 13]
Paclitaxel	N.A.	Non-small Cell Lung Carcinoma	Allele A is associated with decreased transport of paclitaxel in oocytes as compared to allele G.		[ 13]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:         18 Drugs in Total
Paclitaxel	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased anemia risk in patients (compare with genotypes AG + GG)		[ 13]
Carboplatin	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased anemia risk in patients (compare with genotypes AG + GG)		[ 13]
Mycophenolate mofetil	Drug Info	Kidney Transplantation	Correlated with the increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid in patients (compare with genotype GG)		[ 14]
Mycophenolate Mofetil	N.A.	Neutropenia	Genotype AA is associated with increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.		[ 14]
Carboplatin	N.A.	Drug Toxicity	Genotype AA is associated with decreased likelihood of Drug Toxicity when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AG + GG.		[ 27]
Paclitaxel	N.A.	Drug Toxicity	Genotype AA is associated with decreased likelihood of Drug Toxicity when treated with carboplatin and paclitaxel in people with Ovarian Neoplasms as compared to genotypes AG + GG.		[ 27]
Carboplatin	N.A.	Anemia	Genotype AA is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 13]
Paclitaxel	N.A.	Anemia	Genotype AA is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 13]
Warfarin	N.A.	Gastrointestinal Toxicity	Genotype AA is associated with decreased dose of warfarin as compared to genotypes AG + GG.		[ 17]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Genotype AA is associated with increased dose-adjusted area under the curve (AUC6-12) of mycophenolic acid (MPA) when treated with mycophenolate mofetil in people with Kidney Transplantation as compared to genotype GG.		[ 14]
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the AA genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 5]
Carboplatin	N.A.	Non-small Cell Lung Carcinoma	Genotype AA is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 13]
Paclitaxel	N.A.	Non-small Cell Lung Carcinoma	Genotype AA is associated with increased risk of Anemia when treated with carboplatin and paclitaxel in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 13]
Docetaxel	N.A.	Lung Neoplasms	Patients with the AA genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.		[ 2]
Mycophenolic Acid	N.A.	Lung Transplantation	Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Overall Survival	Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have increased survival rates as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Transplant Rejection	Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may be at a decreased risk of transplant rejection as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Chronic Lung Allograft Dysfunction	Patients with the AA genotype who are treated with mycophenolic acid following lung transplantation may have a decreased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AG or GG genotypes. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Genotypes AA + AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Imatinib	N.A.	Neutropenia	Genotypes AA + AG is associated with decreased response to imatinib in people with Leukemia, Myelogenous, Chronic, BCR-ABL Positive as compared to genotype GG.		[ 21]
Methotrexate Polyglutamate	N.A.	Gastrointestinal Toxicity	Genotypes AA + AG is associated with increased concentrations of methotrexate polyglutamate in children with Precursor Cell Lymphoblastic Leukemia-Lymphoma as compared to genotype GG.		[ 27]
Allele G	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Azathioprine	N.A.	Overall Survival	Allele G is not associated with likelihood of overall survival when treated with azathioprine in people with lung transplantation as compared to allele A.		[ 10]
Azathioprine	N.A.	Transplant Rejection	Allele G is not associated with risk of transplant rejection when treated with azathioprine in people with lung transplantation as compared to allele A.		[ 10]
Azathioprine	N.A.	Chronic Lung Allograft Dysfunction	Allele G is not associated with risk of chronic lung allograft dysfunction when treated with azathioprine in people with lung transplantation as compared to allele A.		[ 10]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Mycophenolic Acid	N.A.	Chronic Lung Allograft Dysfunction	Genotypes AG + GG are associated with increased risk of chronic lung allograft dysfunction when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.		[ 10]
Mycophenolic Acid	N.A.	Transplant Rejection	Genotypes AG + GG are associated with increased risk of transplant rejection when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.		[ 10]
Mycophenolic Acid	N.A.	Overall Survival	Genotypes AG + GG are associated with decreased likelihood of overall survival when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.		[ 10]
Mycophenolic Acid	N.A.	Lung Transplantation	Genotypes AG + GG are associated with decreased likelihood of overall survival when treated with mycophenolic acid in people with lung transplantation as compared to genotype AA.		[ 10]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the AG genotype and Kidney Transplantation may have a decreased clearance of mycophenolate mofetil as compared to patients with the GG genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 5]
Carboplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.		[ 13]
Paclitaxel	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.		[ 13]
Docetaxel	N.A.	Lung Neoplasms	Patients with the AG genotype may have increased AUC and decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype GG. Other genetic and clinical factors may also influence the clearance of docetaxel.		[ 2]
Mycophenolic Acid	N.A.	Lung Transplantation	Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Overall Survival	Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Transplant Rejection	Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Chronic Lung Allograft Dysfunction	Patients with the AG genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           8 Drugs in Total
Mycophenolate Mofetil	N.A.	Kidney Transplantation	Patients with the GG genotype and Kidney Transplantation may have an increased clearance of mycophenolate mofetil as compared to patients with the AG or AA genotype. However, contradictory findings are reported. Other genetic and clinical factors may also influence a patient's response to mycophenolate mofetil.		[ 5]
Carboplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.		[ 13]
Paclitaxel	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and Non-Small-Cell Lung Carcinoma who are treated with carboplatin and paclitaxel may have a decreased, but not absent, risk for anemia as compared to patients with the AA genotype. Other genetic and clinical factors may also influence a patient's risk for anemia.		[ 13]
Docetaxel	N.A.	Lung Neoplasms	Patients with the GG genotype may have decreased AUC and increased clearance of docetaxel in people with Nasopharyngeal Neoplasms as compared to patients with genotype AA or AG. Other genetic and clinical factors may also influence the clearance of docetaxel.		[ 2]
Mycophenolic Acid	N.A.	Lung Transplantation	Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Overall Survival	Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have decreased survival rates as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Transplant Rejection	Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may be at an increased risk of transplant rejection as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid. in lung transplant patients.		[ 10]
Mycophenolic Acid	N.A.	Chronic Lung Allograft Dysfunction	Patients with the GG genotype who are treated with mycophenolic acid following lung transplantation may have an increased risk of developing chronic lung allograft dysfunction (CLAD) as compared to patients with the AA genotype. Other genetic and clinical factors may also affect response to mycophenolic acid in lung transplant patients.		[ 10]
Genetic Polymorphism	rs3764006
Site of GPD	chr12:20901435 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C / G>T
Minor Allele Frequency	G=0.3350/662 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Parasitemia	Allele A is not associated with transport of methotrexate in HEK293 cells as compared to allele G.		[ 6]
Genetic Polymorphism	rs2053098
Site of GPD	chr12:20883477 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.3040/601 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Methotrexate	N.A.	Parasitemia	Allele G is not associated with transport of methotrexate in HEK293 cells as compared to allele A.		[ 6]
Genetic Polymorphism	rs3834935
Site of GPD	chr12:20916601 (GRCh38.p12)
GPD Type	Indel
Allele(s) in dbSNP	AAAAAAA / AAAAAAAA / AAAAAAAAA / AAAAAAAAAA
Minor Allele Frequency	AAAAAAAA=0.7300/1444 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Docetaxel	N.A.	Parasitemia	Allele A is associated with increased AUC of docetaxel in people with Nasopharyngeal Neoplasms.		[ 2]
Genetic Polymorphism	rs4149118
Site of GPD	chr12:20858647 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	G=0.4830/955 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Docetaxel	N.A.	Parasitemia	Allele G is associated with decreased clearance of docetaxel in people with Nasopharyngeal Neoplasms.		[ 2]
Genetic Polymorphism	rs60140950
Site of GPD	chr12:20875274 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.9340/1848 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Telmisartan	N.A.	Drug Toxicity	Allele C is associated with increased concentrations of telmisartan in healthy individuals as compared to allele G.		[ 27]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Telmisartan	N.A.	Opioid-related Disorders	Patients with the CC genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.		[ 27]
Genotype CG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Telmisartan	N.A.	Opioid-related Disorders	Patients with the CG genotype may have increased concentrations of telmisartan as compared to patients with the GG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.		[ 27]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Telmisartan	N.A.	Opioid-related Disorders	Patients with the GG genotype may have decreased concentrations of telmisartan as compared to patients with the CC or CG genotype. Other genetic and clinical factors may also influence metabolism of telmisartan. This annotation only covers the pharmacokinetic relationship between SLCO1B3 and telmisartan and does not include evidence about clinical outcomes.		[ 27]
Genetic Polymorphism	rs7977213
Site of GPD	chr12:20827866 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.4210/833 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Leukopenia	Allele G is associated with increased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C.		[ 28]
Genetic Polymorphism	rs10841661
Site of GPD	chr12:20831898 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>T
Minor Allele Frequency	C=0.5650/1118 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Irinotecan	N.A.	Leukopenia	Allele T is associated with increased likelihood of severe myelosuppression when treated with irinotecan in people with Neoplasms as compared to allele C.		[ 28]
References
1	Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
2	Influence of SLCO1B3 haplotype-tag SNPs on docetaxel disposition in Chinese nasopharyngeal cancer patients. Br J Clin Pharmacol. 2012 Apr;73(4):606-18.
3	The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan;23(1):29-33.
4	SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients. Pharmacogenomics. 2010 Dec;11(12):1703-13.
5	The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics. Clin Pharmacol Ther. 2010 Jan;87(1):100-8.
6	Functional consequences of genetic variations in the human organic anion transporting polypeptide 1B3 (OATP1B3) in the Korean population. J Pharm Sci. 2012 Mar;101(3):1302-13.
7	Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients. Pharmacogenomics. 2018 Feb;19(3):175-184.
8	CYP2C9, SLCO1B1, SLCO1B3, and ABCB11 polymorphisms in patients with bosentan-induced liver toxicity. Clin Pharmacol Ther. 2014 Jun;95(6):583-5.
9	Mycophenolic acid-related diarrhea is not associated with polymorphisms in SLCO1B nor with ABCB1 in renal transplant recipients. Pharmacogenet Genomics. 2012 Jun;22(6):399-407.
10	Impact of SLCO1B3 polymorphisms on clinical outcomes in lung allograft recipients receiving mycophenolic acid. Pharmacogenomics J. 2020 Feb;20(1):69-79.
11	Genetic polymorphisms in ABCG2 and CYP1A2 are associated with imatinib dose reduction in patients treated for gastrointestinal stromal tumors. Pharmacogenomics J. 2019 Oct;19(5):473-479.
12	Genetic polymorphisms as predictive biomarker of survival in patients with gastrointestinal stromal tumors treated with sunitinib. Pharmacogenomics J. 2018 Jan;18(1):49-55.
13	Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy. Pharmacogenet Genomics. 2016 Mar;26(3):116-25.
14	Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur J Clin Pharmacol. 2007 Dec;63(12):1161-9.
15	Impacts of SNPs on adverse events and trough concentration of imatinib in patients with gastrointestinal stromal tumors. Drug Metab Pharmacokinet. 2022 Apr;43:100441.
16	SLCO1B3 T334G polymorphisms and mycophenolate mofetil-related adverse reactions in kidney transplant recipients. Pharmacogenomics. 2023 Jan;24(2):83-91.
17	Identification of two novel genes SLC15A2 and SLCO1B3 associated with maintenance dose variability of warfarin in a Chinese population. Sci Rep. 2017 Dec 12;7(1):17379.
18	Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese. Cancer Chemother Pharmacol. 2017 Jun;79(6):1179-1186.
19	Polymorphisms in SLCO1B3 and NR1I2 as genetic determinants of hematotoxicity of carboplatin and paclitaxel combination. Pharmacogenomics. 2015;16(13):1439-50.
20	Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics. 2018 Jul 01;19(11):913-925.
21	Relationship between SLCO1B3 and ABCA3 polymorphisms and imatinib response in chronic myeloid leukemia patients. Hematology. 2015 Apr;20(3):137-42.
22	Genotype-Guided Model for Prediction of Tacrolimus Initial Dosing After Lung Transplantation. J Clin Pharmacol. 2024 Jun;64(6):719-727.
23	Effects of SCT genetic polymorphisms on methotrexate concentrations and toxicities in Chinese children with acute lymphoblastic leukemia. Leuk Lymphoma. 2025 Jun;66(6):1068-1078.
24	Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenet Genomics. 2023 Jun 01;33(4):79-87.
25	Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high-grade serous ovarian cancer. Basic Clin Pharmacol Toxicol. 2023 Jun;132(6):521-531.
26	Genetic polymorphisms and their association with methotrexate polyglutamates during maintenance treatment in Korean children and young adults with acute lymphoblastic leukemia. Eur J Pharm Sci. 2024 Nov 01;202:106878.
27	UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics-A Comprehensive Pharmacogenomic Study. Clin Pharmacol Ther. 2020 Oct;108(4):885-895.
28	Single nucleotide polymorphism in ABCG2 is associated with irinotecan-induced severe myelosuppression. J Hum Genet. 2009 Oct;54(10):572-80.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.